Successful treatment of palmoplantar pustulosis with rheumatoid arthritis, with tofacitinib: Impact of this JAK inhibitor on T-cell differentiation

Clinical Immunology

Volumn 173, Issue , 2016, Pages 147-148

  Koga, Tomohiro ^a   Sato, Tomohito ^a   Umeda, Masataka ^a   Fukui, Shoichi ^a   Horai, Yoshiro ^a,b   Kawashiri, Shin ya ^a   Iwamoto, Naoki ^a   Ichinose, Kunihiro ^a   Nakamura, Hideki ^a   Kawakami, Atsushi ^a  

^a NAGASAKI UNIVERSITY GRADUATE SCHOOL OF BIOMEDICAL SCIENCES   (Japan)

^b NATIONAL HOSPITAL ORGANIZATION NAGASAKI MEDICAL CENTER   (Japan)

Author keywords

Palmoplantar pustulosis; Rheumatoid arthritis; Th1 cells; Th17 1 cells; Tofacitinib

Indexed keywords

ADALIMUMAB; C REACTIVE PROTEIN; METHOTREXATE; TOFACITINIB; ANTIRHEUMATIC AGENT; JANUS KINASE INHIBITOR; PIPERIDINE DERIVATIVE; PYRIMIDINE DERIVATIVE; PYRROLE DERIVATIVE;

ADULT; CASE REPORT; DISEASE ACTIVITY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; ERYTHEMA; ERYTHROCYTE SEDIMENTATION RATE; FEMALE; FLOW CYTOMETRY; HUMAN; LETTER; LYMPHOCYTE DIFFERENTIATION; MEMORY T LYMPHOCYTE; MIDDLE AGED; PRIORITY JOURNAL; PUSTULE; PUSTULOSIS PALMOPLANTARIS; RHEUMATOID ARTHRITIS; TENOSYNOVITIS; TH1 CELL; COMPLICATION; PSORIASIS; TREATMENT OUTCOME;

ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; FEMALE; HUMANS; JANUS KINASE INHIBITORS; MIDDLE AGED; PIPERIDINES; PSORIASIS; PYRIMIDINES; PYRROLES; TREATMENT OUTCOME;

EID: 84994403987     PISSN: 15216616     EISSN: 15217035     Source Type: Journal    
DOI: 10.1016/j.clim.2016.10.003     Document Type: Letter

References (10)

1. [1] Eriksson, M.O., Hagforsen, E., Lundin, I.P., Michaelsson, G., Palmoplantar pustulosis: a clinical and immunohistological study. Br. J. Dermatol. 138 (1998), 390–398.
2. [2] Torii, K., Furuhashi, T., Saito, C., Kato, H., Nishioka, A., Nishida, E., Shintani, Y., Morita, A., Increased peripheral Th17 in patients with pustulosis palmaris et plantaris. Arch. Dermatol. Res. 303 (2011), 441–444.
3. [3] Hagforsen, E., Hedstrand, H., Nyberg, F., Michaelsson, G., Novel findings of Langerhans cells and interleukin-17 expression in relation to the acrosyringium and pustule in palmoplantar pustulosis. Br. J. Dermatol. 163 (2010), 572–579.
4. [4] Murakami, M., Hagforsen, E., Morhenn, V., Ishida-Yamamoto, A., Iizuka, H., Patients with palmoplantar pustulosis have increased IL-17 and IL-22 levels both in the lesion and serum. Exp. Dermatol. 20 (2011), 845–847.
5. [5] Ibis, N., Hocaoglu, S., Cebicci, M.A., Sutbeyaz, S.T., Calis, H.T., Palmoplantar pustular psoriasis induced by adalimumab: a case report and literature review. Immunotherapy 7 (2015), 717–720.
6. [6] Ghoreschi, K., Gadina, M., Jakpot! New small molecules in autoimmune and inflammatory diseases. Exp. Dermatol. 23 (2014), 7–11.
7. [7] Rueda-Gotor, J., Gonzalez-Gay, M.A., Blanco Alonso, R., Gonzalez-Vela, C., Lopez-Obregon, C., Gonzalez-Lopez, M.A., Successful effect of tocilizumab in anti-TNF-alpha-induced palmoplantar pustulosis in rheumatoid arthritis. Joint Bone Spine 79 (2012), 510–513.
8. [8] Jayasekera, P., Parslew, R., Al-Sharqi, A., A case of tumour necrosis factor-alpha inhibitor- and rituximab-induced plantar pustular psoriasis that completely resolved with tocilizumab. Br. J. Dermatol. 171 (2014), 1546–1549.
9. [9] Bissonnette, R., Nigen, S., Langley, R.G., Lynde, C.W., Tan, J., Fuentes-Duculan, J., Krueger, J.G., Increased expression of IL-17A and limited involvement of IL-23 in patients with palmo-plantar (PP) pustular psoriasis or PP pustulosis; results from a randomised controlled trial. J. Eur. Acad. Dermatol. Venereol. 28 (2014), 1298–1305.
10. [10] Puig, L., Morales-Munera, C.E., Lopez-Ferrer, A., Geli, C., Ustekinumab treatment of TNF antagonist-induced paradoxical psoriasis flare in a patient with psoriatic arthritis: case report and review. Dermatology 225 (2012), 14–17.